EUVIMEDEUVIMED entdecken
Crossref

TREATMENT OF IMPETIGO WITH TOPICAL ANTISEPTICS LEADS TO MORE RESIDUAL BACTERIA ON THE SKIN AFTER TREATMENT BUT NOT EARLIER RECURRENCE OF INFECTION

Sarah Primhak, Alison Leversha, Emma Best

Excellence in Pediatrics Abstracts · 04.12.2025 · 17

DOI: 10.66584/eip2025-122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Excellence in Pediatrics Abstracts, online erschienen am 04.12.2025. Verfasst von Sarah Primhak und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Antiseptics are increasingly being used to treat impetigo in order to reduce the development of antimicrobial resistance due to topical antibiotic prescribing. Our recent randomised controlled trial compared treatment of non-severe impetigo using topical antiseptic hydrogen peroxide and topical antibiotic fusidic acid. Use of antiseptic was not shown to be non-inferior overall when compared to antibiotics. However, antiseptics led to non-inferior treatment outcomes when participants with impetigo affecting multiple body areas were excluded, implying treatment of localised impetigo was non-inferior with topical antiseptics. Higher rates of residual bacteria, both Staphylococcus aureus and Streptococcus pyogenes, were identified on the skin at the end of treatment with antiseptic when compared to antibiotic. This raised questions about the potential for early recurrences in this group. The aim of this study was to follow-up trial participants to identify differences in time to next skin and soft tissue infection (SSTI) between those treated with antiseptic and antibiotic.

Method

Health records for each participant, including school health records, community prescriptions, and hospital visits, were reviewed for each study participant to identify presentations for SSTIs and compared using Kaplan Meier survival curves and Log rank tests.

Results

391/400 participants had complete follow-up data. Following completion of the trial 28/154 (18%) of participants given antibiotic and 34/164 (21%) of participants who received antiseptic experienced a SSTI within 30 days. There was no significant difference demonstrated between time to first recurrence (Log rank test X2 0.4, p=0.5).

Conclusion

When treating non-severe, localised impetigo with topical antiseptics, more bacteria remain on the skin after treatment, but based on this small sample, there is no evidence of early recurrence of SSTI in those treated with topical antiseptics when compared to topical antibiotics. This provides support for the treatment of non-severe impetigo with antiseptics, a practice that is increasing in several countries, including the UK and New Zealand.

Zitieren

APA

Primhak, S., Leversha, A., & Best, E. (2025). TREATMENT OF IMPETIGO WITH TOPICAL ANTISEPTICS LEADS TO MORE RESIDUAL BACTERIA ON THE SKIN AFTER TREATMENT BUT NOT EARLIER RECURRENCE OF INFECTION. Excellence in Pediatrics Abstracts, 17. https://doi.org/10.66584/eip2025-122

Vancouver

Primhak S, Leversha A, Best E. TREATMENT OF IMPETIGO WITH TOPICAL ANTISEPTICS LEADS TO MORE RESIDUAL BACTERIA ON THE SKIN AFTER TREATMENT BUT NOT EARLIER RECURRENCE OF INFECTION. Excellence in Pediatrics Abstracts. 2025;17. doi:10.66584/eip2025-122

BibTeX
@article{Primhak2025,
  author = {Primhak, Sarah and Leversha, Alison and Best, Emma},
  title = {TREATMENT OF IMPETIGO WITH TOPICAL ANTISEPTICS LEADS TO MORE RESIDUAL BACTERIA ON THE SKIN AFTER TREATMENT BUT NOT EARLIER RECURRENCE OF INFECTION},
  journal = {Excellence in Pediatrics Abstracts},
  year = {2025},
  volume = {17},
  doi = {10.66584/eip2025-122}
}
Kostenlos starten →